Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
597results about "Albumin peptides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Serum albumin binding proteins with long half-lives
InactiveUS20070269422A1Increased serum half-lifeReduce dosing frequencyOrganic active ingredientsPeptide/protein ingredientsSerum igePrimate
The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides. Particularly, the amino acid sequences and compounds of the present invention bind to or otherwise associate with serum albumin in such a way that, when the amino acid sequence or compound is bound to or otherwise associated with a serum albumin molecule in a primate, it exhibits a serum half-life of at least 50% of the natural half-life of serum albumin in said primate.
Owner:ABLYNX NV
Sclerostin-binding antibody
Owner:UCB SA +1
Long lasting synthetic glucagon-like peptide {GLP-1}
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Owner:CONJUCHEM
Proteinaceous pharmaceuticals and uses thereof
InactiveUS20070191272A1High disulfide densityReduce molecular weightPeptide librariesNervous disorderCysteine thiolateBiology
The present invention provides cysteine-containing scaffolds and / or proteins, expression vectors, host cell and display systems harboring and / or expressing such cysteine-containing products. The present invention also provides methods of designing libraries of such products, methods of screening such libraries to yield entities exhibiting binding specificities towards a target molecule. Further provided by the invention are pharmaceutical compositions comprising the cysteine-containing products of the present invention.
Owner:AMUNIX OPERATING INC
Megalin-based delivery of therapeutic compounds to the brain and other tissues
InactiveUS20050042227A1Easy to transportImprove propertiesBiocideNervous disorderBlood–brain barrierDrug delivery
Owner:HORIZON ORPHAN LLC
Method of providing hemostasis to a wound
The present invention is directed to hemostatic wound dressings that contain a substrate for contacting a wound, wherein the substrate includes a wound-contacting surface and is fabricated at least in part from a biocompatible aldehyde-modified polysaccharide having covalently conjugated there with a hemostatic agent and to methods of providing hemostasis to a wound that include applying the wound dressing described herein to a wound.
Owner:ETHICON INC
Reducing the immunogenicity of fusion proteins
InactiveUS6992174B2Low immunogenicityHigh expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsMHC class IIVaccine Immunogenicity
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
Owner:MERCK PATENT GMBH
Compounds and methods for treatment of thrombosis
InactiveUS20050143317A1Good water solubilityGood cell membrane permeabilityPeptide/protein ingredientsMicrobiological testing/measurementThrombusMedicinal chemistry
The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
Owner:EXITHERA PHARMA
Method for treating amyloid disease
InactiveUS20070010435A1Reduce the burden onEasy to transportBiocideOrganic active ingredientsAmyloid betaPlasma Exchanges
Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange in order to remove Aβ peptides from the blood circulation, and / or brain or other affected organs.
Owner:NEW YORK UNIVERSITY
Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
ActiveUS20070117744A1Improve stabilityImprove filtering effectBiocideNanotechSide effectMicrobial agent
The present invention provides compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, and an antimicrobial agent, wherein significant microbial growth is inhibited in the composition. The amount of the antimicrobial agent in the composition may be below the level that induces a toxicological effect or at a level where a potential side effect can be controlled or tolerated. Also provided are compositions comprising a poorly water soluble pharmaceutical agent, a carrier protein, a sugar, and optionally an antimicrobial agent. Methods of using the compositions are also provided.
Owner:ABRAXIS BIOSCI LLC
Materials and methods for modulating metabolism
InactiveUS20050245433A1High expressionIncrease adiponectin levelBiocideSenses disorderDiabetes mellitusCysteamine
The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and / or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and / or treat or prevent the onset of diabetes-associated complications.
Owner:OMEGA BIO PHARMA I P 3
Compounds and methods for treatment of thrombosis
InactiveUS7217794B2Increase ligant affinityGood water solubilityPeptide/protein ingredientsAlbumin peptidesMedicineMammal
The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
Owner:EXITHERA PHARMA
Method of treatment of diabetes and/or obesity with reduced nausea side effect
InactiveUS20070207958A1Prevent and reduce and eliminate nausea side effectReduces and eliminates side effectPeptide/protein ingredientsMetabolism disorderSide effectInsulinotropin
The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.
Owner:CONJUCHEM
Modified RNA with decreased immunostimulatory properties
ActiveUS20160235864A1Reduce innate immune responseIncrease mRNA levelsOrganic active ingredientsPeptide/protein ingredientsVaccine ImmunogenicityRNA
The present invention provides a method for providing modified mRNAs of reduced immunogenicity and / or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
Owner:CUREVAC SE
Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
InactiveUS20050282734A1Prevent restenosisFree of organic solventsBiocideOrganic active ingredientsOrganic solventSerum protein albumin
An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10% organic solvent and has a pH of about 3.0 to about 4.8, is described. The serum albumin can be fatted or defatted, and the composition can optionally be lyophilized or optionally lyophilized and reconstituted. At least 70% of the paclitaxel is bound to serum albumin, the ratio of paclitaxel to albumin is at least about 1:5, and the concentration of paclitaxel is at least about 25 μg / ml. Methods of making and using this composition an also provided.
Owner:KADIMA TENSHUK A +6
Hydrogel-containing medical articles and methods of using and making the same
InactiveUS20050214376A1Efficient use ofCheap to makePowder deliveryBiocidePolyethylene glycolDiazolidinyl urea
Medical articles including a hydrophilic water-swellable hydrogel and methods of using and making the articles are provided. The hydrogel may include a crosslinked mixture of a biocompatible polymer and a protein, such as polyethylene glycol and a soy protein. The hydrogel may further include an agent, such as diazolidinyl urea and iodopropynyl butylcarbamate, dispersed within the hydrophilic water-swellable hydrogel.
Owner:BIOARTIFICIAL GEL TECH
Modified Proteins
InactiveUS20080108557A1Prolonged Circulatory Half-LifeReduce in quantityPeptide/protein ingredientsAlbumin peptidesGlycosyltransferasePeptide
Owner:NOVO NORDISK AS
Methods for treatment of acute pancreatitis
The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier.
Owner:CHIRHOCLIN
Factor IX Polypeptides and Methods of Use Thereof
Owner:BIOVERATIV THERAPEUTICS INC
Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.
Owner:KRATZ FELIX
Methods of enhancing drug delivery and effectiveness of therapeutic agents
ActiveUS20120076862A1Promote absorptionConvenient treatmentPowder deliveryHeavy metal active ingredientsDiseaseCo administration
The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.
Owner:ABRAXIS BIOSCI LLC
Method for treatment and repair of meniscal injuries
Owner:OCUGEN INC +1
Anti-obesity agents
InactiveUS20050176643A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.
Owner:CONJUCHEM
Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
InactiveUS20130045240A1Organic active ingredientsPowder deliveryHedgehog signaling pathwayNanoparticle
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.
Owner:ABRAXIS BIOSCI LLC
Pharmaceutical Formulation and Process
InactiveUS20070196364A1Increased Tg′Less-dramatic effectOrganic active ingredientsBiocideSucroseActive agent
A process for lyophilization or freeze-drying of a pharmaceutical product is provided and a liquid formulation suitable for lyophilization. In particular, a process for lyophilization or freeze-drying a liquid formulation that includes a protein active agent, a bulking agent and a saccharide stabilizing agent is provided. The saccharide to bulking agent ratio and the protein concentration of the formulation are important factors that affect crystallization of the bulking agent during lyophilization and storage as are some processing conditions. In one embodiment, the saccharide is a disaccharide, such as sucrose and the crystalline bulking agent is mannitol. The protein can be an antibody or a non-antibody protein.
Owner:HUMAN GENOME SCI INC
Methods of treating bladder cancer
InactiveUS20140056986A1Many symptomDelaying progressing of bladder cancerPowder deliveryPeptide/protein ingredientsNanoparticleSurgery
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.
Owner:ABRAXIS BIOSCI LLC
Glycopegylated erythropoietin formulations
InactiveUS20060287224A1Improved pharmacokinetic propertiesCost effectiveOrganic active ingredientsBiocideDiseasePharmaceutical formulation
The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
Owner:NOVO NORDISK AS
FGFR Extracellular Domain Acidic Region Muteins
InactiveUS20100087627A1Decreased ECM bindingImprove bioavailabilitySenses disorderPeptide/protein ingredientsMutated proteinPolynucleotide
Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.
Owner:FIVE PRIME THERAPEUTICS
Nonexpansion Protocol for Autologous Cell-Based Therapies
InactiveUS20070224173A1Increased risk of contaminationIncrease the number of cellsBiocideOrganic active ingredientsHeterologousCell-Extracellular Matrix
The present application describes various applications of the non-expansion protocol for the preparation of an injectable autologous cell mixture of the present invention that can be used to prevent symptoms in a number of indications. Cells are isolated from surgically derived tissue and are at least partially disaggregated from each other. The heterologous cell mixture is mixed with growth factors, differentiation agents, extracellular matrix proteins and / or microspheres and injected into the patient without cell expansion. The harvesting of tissue, cell isolation, and injection are performed within a single surgical procedure lasting only minutes to hours.
Owner:BOSTON SCI SCIMED INC
Methods of treatment of pancreatic cancer
ActiveUS20130202709A1Many symptomShorten the progressBiocidePeptide/protein ingredientsNanoparticlePreviously treated
The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.
Owner:ABRAXIS BIOSCI LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com